Hematocrit Below Reference Limit: What It Means

What hematocrit actually measures, and how it differs from hemoglobin

Hematocrit and hemoglobin are related but distinct. Hemoglobin measures the concentration of the oxygen-carrying protein inside red blood cells, in grams per deciliter. Hematocrit measures the fraction of total blood volume those red cells occupy, as a percentage. They move together and hematocrit is roughly three times the hemoglobin value in most people, but a clinician may order or interpret them differently depending on the question being asked (for example, transfusion thresholds are usually written in hemoglobin, not hematocrit).

A standard venous blood draw fills an EDTA tube and a hematology analyzer reports hematocrit, hemoglobin, red cell count, and red cell indices (including mean corpuscular volume, or MCV) together as part of the CBC. Fasting is not required. Hydration status, however, changes the reading independent of true red cell mass: a dehydrated patient shows a falsely elevated hematocrit because plasma volume has contracted around an unchanged number of red cells. This is the single most common reason a borderline-high result should be repeated under controlled hydration before anyone talks about a diagnosis.

Normal ranges and what shifts them without disease

Reference ranges differ slightly by laboratory and analyzer, but adult ranges commonly fall around 38% to 49% for men and 35% to 45% for women. The sex difference is attributed largely to testosterone's stimulation of erythropoietin (EPO) production, which drives red cell synthesis in bone marrow.

Several physiologic factors shift hematocrit without indicating disease:

• Altitude. People living at high altitude typically run somewhat higher hematocrit than sea-level populations, because the body compensates for lower ambient oxygen by producing more red cells.
• Age. Newborns run much higher than adults and this falls over the first weeks of life. Some older adults trend lower, plausibly from reduced renal EPO output or chronic low-grade inflammation.
• Pregnancy. Plasma volume expands faster than red cell mass in pregnancy, producing an expected dilutional drop in hematocrit, particularly in the second trimester. This is a normal physiologic finding, not by itself evidence of iron-deficiency anemia.
• Smoking. Carbon monoxide from cigarettes reduces the oxygen-carrying capacity of existing hemoglobin, which can trigger a compensatory rise in red cell production.

A value at the very top or bottom of "normal" still deserves context. A hematocrit at the upper edge of the male range in a young woman, for instance, is worth a conversation with a clinician even though it may not be flagged by the lab.

What is established: the general direction and existence of these effects is well described in the hematology and endocrinology literature. What is not established on this page: the precise magnitude of each effect (how many percentage points altitude or smoking adds, for example) varies across studies and populations, and a reader should not treat any single figure as a personal prediction.

High hematocrit: three different problems that look the same on paper

A hematocrit above the reference range is called erythrocytosis, and the causes split into three categories that require different workups.

Relative erythrocytosis is the most common explanation in everyday practice. Dehydration, diuretic use, or fluid loss from vomiting or illness contracts plasma volume and concentrates red cells without any real increase in red cell mass. Rehydrating and repeating the draw typically resolves it.

Primary erythrocytosis points toward polycythemia vera (PV), a bone marrow disorder associated with a JAK2 mutation in the large majority of cases. Current hematology classification criteria use hematocrit thresholds in the high 40s (roughly 49% in men, 48% in women) as part of the criteria that prompt further workup for PV, alongside other findings. PV is associated with meaningfully elevated risk of blood clots and cardiovascular events, and clinical trial evidence supports keeping hematocrit below a defined target (commonly cited as below 45%) in confirmed PV to reduce that risk, though a reader should verify the exact trial results and effect size against the primary literature rather than rely on a single number repeated online.

Secondary erythrocytosis results from EPO overproduction driven by chronic low oxygen states, such as obstructive sleep apnea, COPD, or heart conditions that shunt blood past the lungs. EPO-producing tumors (in the kidney, liver, or brain) are rare causes that are considered when no hypoxic explanation is found.

Distinguishing these three categories usually requires more than the hematocrit number alone: a repeat test after hydration, an oxygen saturation check, a sleep study if indicated, and in some cases JAK2 testing and a hematology referral.

Testosterone therapy and hematocrit

Erythrocytosis is the most frequently reported laboratory change associated with testosterone replacement therapy (TRT), and it is dose- and route-dependent. Randomized trial evidence in older hypogonadal men has shown a measurable rise in hematocrit with testosterone treatment compared with placebo, and larger cardiovascular-safety trials have reported higher rates of clinically significant polycythemia (hematocrit above 54%) in testosterone-treated groups than in placebo groups. The exact percentage-point increases and event rates vary by trial population, formulation, and duration, and a reader relying on a specific number for personal risk should ask their prescriber to walk through the source trial rather than treat a headline figure as individualized guidance.

The Endocrine Society's testosterone therapy guideline recommends checking hematocrit at baseline, around 3 to 6 months after starting therapy, and then at least annually, and recommends holding testosterone if hematocrit rises above 54% until it comes back down to a safer level. That threshold reflects the point at which blood viscosity is understood to rise sharply and thrombotic risk with it; this is guideline-level recommendation, not a hard biological cutoff that applies identically to every patient.

A general monitoring sequence that follows this guidance:

1. Baseline CBC before starting testosterone therapy.
2. Recheck around 3 months; if hematocrit is elevated, confirm hydration status and repeat before acting.
3. Recheck around 6 months; if confirmed persistently above the guideline threshold, the prescriber may hold therapy, consider phlebotomy, and reassess dose or formulation once hematocrit falls back to a safer range.
4. Ongoing monitoring, typically annual, once stable.

Switching from intramuscular injections (which produce higher peak hormone levels) to transdermal or other steadier-release formulations is a strategy some clinicians use to blunt erythrocytosis, though the comparative evidence between formulations is limited and should be discussed with a prescriber rather than self-directed.

Low hematocrit: what the MCV tells you next

A hematocrit below the reference range defines anemia. The World Health Organization defines anemia using hemoglobin thresholds (below 13 g/dL in men, below 12 g/dL in non-pregnant women), which correspond approximately to the low hematocrit values most labs flag (WHO, anaemia in women and children).

The mean corpuscular volume (MCV) reported on the same CBC narrows the differential quickly:

• Microcytic (MCV below about 80 fL): most often iron deficiency. In premenopausal women, menstrual blood loss is the most common driver; in men and postmenopausal women, gastrointestinal blood loss needs to be ruled out. A low ferritin is commonly used to support the diagnosis, though ferritin can be falsely normal or elevated in the presence of inflammation, so interpretation should involve a clinician.
• Normocytic (MCV roughly 80 to 100 fL): suggests chronic disease (kidney disease, chronic inflammation, malignancy), acute blood loss, or hemolysis. A reticulocyte count, LDH, haptoglobin, and creatinine help sort these.
• Macrocytic (MCV above about 100 fL): points toward vitamin B12 or folate deficiency, heavy alcohol use, hypothyroidism, or, less commonly, a bone marrow disorder.

Treatment depends entirely on the underlying cause, and specific dosing of iron, B12, or other therapies should come from the prescribing clinician rather than a general reference, since dose depends on severity, tolerance, kidney function, and the reason for the deficiency.

A separate line of evidence worth noting for context, not personal dosing guidance: animal studies have used iron supplementation to correct diet-induced iron deficiency in mouse models, demonstrating that iron repletion restores iron status in a controlled experimental setting (iron syrup supplementation in a mouse model of diet-induced iron deficiency, 2021). This is preclinical, rodent-model evidence. It supports the general biological principle that iron repletion corrects iron-deficient states, but it does not establish a human dose, timeline, or formulation and should not be read as clinical guidance.

Lowering or raising hematocrit: the strategy depends on the cause, not the number

There is no single intervention that "lowers" or "raises" hematocrit safely across every cause. The correct next step depends on why the number is abnormal:

• If the cause is dehydration, increasing fluid intake and rechecking in one to two weeks is usually sufficient.
• If the cause is confirmed polycythemia vera, hematology-directed therapeutic phlebotomy and, in many cases, cytoreductive medication are used, with a hematocrit target commonly set below 45% based on randomized trial evidence in PV specifically. This target and the associated risk reduction are trial findings; the exact magnitude of benefit should be verified against the primary trial report rather than repeated as a fixed number.
• If the cause is TRT-related erythrocytosis, the options are guideline-directed: hold or reduce testosterone dose, consider a different formulation, or use therapeutic phlebotomy, decided with the prescriber.
• If the cause is chronic hypoxia (for example, untreated sleep apnea), treating the underlying condition (such as starting CPAP) is the more durable fix than treating the blood count in isolation.
• If the cause is iron-deficiency anemia, iron repletion (oral or, when indicated, intravenous) under clinical supervision is standard; correction typically takes weeks to a few months, and the exact timeline depends on severity and how well the underlying cause of blood loss is controlled.
• If the cause is B12 or folate deficiency, replacement of the specific deficient vitamin, with a route and schedule set by the prescriber, is standard.

Donating blood is not a substitute for a supervised phlebotomy plan for elevated hematocrit. Blood banks screen for polycythemia, and repeated donation without addressing iron stores can create a new iron-deficiency problem even as hematocrit falls.

When a result needs urgent attention versus a routine recheck

Not every abnormal hematocrit is an emergency. A single borderline-high value in someone who is otherwise well and possibly dehydrated is reasonably handled with a repeat test in a matter of weeks. A markedly elevated value accompanied by headache, visual changes, dizziness, or burning pain in the hands or feet (symptoms associated with hyperviscosity) is not something to sit on, and same-day evaluation is appropriate.

On the low side, anemia with symptoms such as chest pain, rapid heartbeat, or shortness of breath at rest, or a hemoglobin low enough to raise concern for hemodynamic instability, warrants urgent evaluation for possible transfusion. Mild, asymptomatic anemia can typically be worked up as an outpatient.

If you are on testosterone therapy, or if a result looks abnormal alongside symptoms, do not wait for a routine follow-up: contact the prescribing or primary care clinician promptly rather than adjusting a supplement, dose, or therapy on your own.

A decision framework for an abnormal hematocrit result

This framework is meant to organize the next question a reader should ask, not to replace a clinician's workup.

Step 1: Is this a single value or a confirmed trend? A one-off abnormal result, especially near the edge of the reference range, should generally be repeated under controlled hydration before further workup. A confirmed trend across two or more draws is a different situation than a single flagged number.

Step 2: Which direction, and how far from the range?

Step 3: What does the MCV or clinical context point to? For high values: is there a plausible hydration or altitude explanation, a hypoxic condition (sleep apnea, lung disease), a hormone therapy effect, or none of the above (which raises the question of a primary marrow process)? For low values: does the MCV suggest iron deficiency, a chronic disease/inflammatory pattern, or a B12/folate pattern?

Step 4: Does the finding change urgency, or just monitoring frequency? Most abnormal hematocrit values change how often you get rechecked, not whether you need to go to an emergency department. The symptoms listed in Step 2, not the number alone, are what should prompt urgent care.

Exceptions worth naming. Pregnancy produces an expected drop in hematocrit that should not be treated as anemia by the same rules as a non-pregnant adult. Endurance athletes can show temporary shifts around intense training that resolve without treatment. Someone recently started on testosterone therapy needs a monitoring schedule set by their prescriber rather than the general intervals used for people not on hormone therapy.

Evidence boundary. Established: the general physiology of hematocrit, the existence and direction of the factors that shift it (altitude, age, pregnancy, smoking, hydration), the WHO anemia definitions, and the fact that testosterone therapy raises hematocrit and requires monitoring per the Endocrine Society guideline. Plausible but requiring primary-source verification for this page: exact percentage-point effect sizes, exact trial event rates, and specific hazard ratios that are commonly quoted in secondary sources about polycythemia vera and TRT trials. Not established on this page: any individualized dose, personal risk number, or diagnosis; those require direct clinical evaluation.